$PBIO Mr. Bradley, CEO of RedShiftBio, stated: “…accelerated stability testing in formulations development could potentially be reduced to weeks, if not days. Consequently, the PCT-enhanced MMS platform could potentially be used to achieve new drug approvals in significantly less time than required today.”